@inproceedings{inproceedings, title  = {{A randomised, double-blind phase II study of autogene cevumeran plus nivolumab (nivo) vs. nivo as adjuvant therapy for patients with high-risk muscle-invasive urothelial carcinoma (MIUC)}},

 url = {{}},

 year = {{2025}},

 month = {{3}},

 author = {{Catto JWF and Aggen D and Petros G and Loriot Y and Puente J and Sridhar SS and Ianculescu II and Vuky J and Degaonkar V and Liu LX and Yadav M et al}},

 volume = {{87}},

 journal = {{EUROPEAN UROLOGY}},

 note = {{Accessed on 2025/12/12}}}